💸 The Tape

Senate appropriators handed the hemp industry a reprieve over the weekend, and the trade groups responded roughly the way you'd expect — with a Mark Twain riff about reports of death being exaggerated and a press release calling it the sector's biggest win since the 2018 Farm Bill.

It is not. It is a four-week postponement of a firing squad, contingent on a chamber that hasn't voted, attached to a vehicle that historically gets ransacked, with a carve-out that guts most of the benefit. Anyone treating this as a resolution is going to have a very unpleasant December.

Here's what actually happened, and then here's why you should stay seated.

The facts

On Sunday, Senate Appropriations Committee leaders released text of a bill extending federal agency funding through December 11, past the current fiscal year's end on September 30. Included are provisions delaying the planned prohibition on most hemp products until that same date — with a carve-out permitting immediate recriminalization on November 12 of synthetic cannabinoids not capable of being naturally produced by a cannabis plant.

For context: hemp derivatives below 0.3% delta-9 THC were legalized under the 2018 Farm Bill, but legislation signed late last year redefines hemp so that only products with 0.4 milligrams of total THC per container remain legal after November 12.

So the ban moves from November 12 to December 11. Twenty-nine days.

Reason one: it isn't law, and the House is the obstacle

This is Senate committee text. It has not passed the Senate. And critically — the House passed its own continuing resolution last month containing no hemp provisions whatsoever, meaning the Senate language would still require approval from the other chamber before reaching the president.

The House already voted once and declined to touch this. Asking it to vote again, on different text, under time pressure, in an election year, is not a formality. It's the whole ballgame — and nobody has demonstrated the votes.

Reason two: the vehicle is a continuing resolution

Of all the legislative conveyances available, appropriators picked the one most likely to be stripped, renegotiated or blown up entirely. CRs are where policy riders go to die. The fiscal year ends September 30. If the fall brings the shutdown standoff Washington has produced with near-metronomic reliability, hemp language becomes a bargaining chip — and it will be traded by people who do not care about delta-8 gummies.

Betting your inventory plan on a rider surviving a shutdown fight is not risk management. It's optimism with a business license.

Reason three: the carve-out does most of the damage anyway

Read the exception again. Synthetic cannabinoids get recriminalized on November 12 regardless.

Commercially, delta-8 and most of the isomer catalog are synthesized from CBD, not harvested. That's the category that built the gas-station THC economy. This "lifeline" protects full-spectrum CBD and beverages — the products with mainstream lobbying muscle behind them, from the restaurant association to Target — while the isomer business keeps its original execution date.

That's not an accident. It's the compromise. But it means the delay saves considerably less of the market than the celebration implies.

Reason four: the White House support is softer than advertised

Trump has publicly pressed Congress to preserve access to full-spectrum CBD while restricting products that pose health risks, and OMB Director Russell Vought wrote Speaker Johnson urging fair treatment of hemp products. That sounds like backing.

Look closer. The president's ask is specifically about CBD, framed around Medicare beneficiaries and farmers — not intoxicating hemp. And on the leading legislative fix: Rep. Andy Barr's office claimed White House support for his bipartisan bill with Rep. Angie Craig, but the administration has never specifically endorsed it and reportedly has problems with the inhalable product provisions.

Meanwhile the Wine & Spirits Wholesalers of America praised Barr's bill but said its tax provisions require continued discussion — trade-association Esperanto for we have not agreed on the money. The alcohol lobby is not a bystander here.

Reason five: the actual tell

Buried in the coverage is the sentence that matters most. Lawmakers in both chambers and both parties have filed a growing number of bills to prevent recriminalization — and until now, none of them gained traction with congressional leaders.

Rep. James Comer is circulating one. Barr filed a longer one. A Senate companion is expected from Sens. Tim Sheehy and Amy Klobuchar. That's a great deal of legislative activity producing exactly zero enacted statute.

A 29-day delay smuggled into a spending bill is not evidence that Congress is converging on hemp policy. It's evidence that Congress cannot pass hemp policy on its own merits and has resorted to attaching it to must-pass funding — which is what you do when the standalone bill can't get a floor vote.

And note where December 11 lands you: the next government funding deadline, which the Hemp Roundtable's own counsel has identified as the target for a comprehensive fix. Same cliff. Same dysfunction. Holiday calendar. Merry Christmas.

What operators should actually do

Two practical points.

First, rolling uncertainty is worse than a fixed date. A business can plan around a ban — liquidate, pivot, exit. It cannot plan around maybe. Try explaining a 29-day extension to a landlord, an insurer, or a lender underwriting a term loan. Capital does not price "we'll know in December."

Second, and more important for the licensed side: none of this reopens Texas or Ohio. Texas's controlled-substance definitions took effect July 31 by state action. Ohio's SB 56 routed intoxicating hemp exclusively into licensed dispensaries back in March. Those are state laws, unaffected by any federal delay — and polling already shows state bans pushing consumers toward licensed marijuana retailers.

For MSOs operating in states that have already acted, the federal fight is noise. Their channel-shift benefit is banked. For hemp operators, the federal fight is everything — and they just got a stay of execution, not a pardon.

Twenty-nine days, one chamber short, with the synthetics dying on schedule anyway.

That's not a win. That's a continuance.

📈 Dog Walkers

Lolla Catches An Alternative Buzz

Green Thumb Industries just put hemp THC beverages inside Grant Park. Through its RYTHM Inc. subsidiary, the company's Señorita brand — margarita-style canned cocktails with 5mg of hemp-derived THC per 12-ounce can — made its Lollapalooza debut this weekend, sold to fans 21 and up at $16, the same price point as alcohol.

CEO Ben Kovler called beverages a major category going forward, and the receipts support him. Señorita is now on the menu at more than 80 independent Chicago venues, including the Riviera, Vic and Ramova, and earlier this year the United Center became the first major U.S. arena to carry THC drinks. One Lolla bar manager reported selling out of mango on day one.

The demand signal is real. A 2026 consumer study found 76.6% of respondents had cut alcohol consumption in favor of THC drinks, with 21.1% abandoning beer and wine entirely — and Chicago venues need it, with only one in four independent rooms reporting profitability last year.

Here's the catch nobody at the festival was thinking about. Illinois passed legislation in June regulating delta-8 and other intoxicating hemp products like recreational marijuana. When it takes effect in November, Señorita may be dispensary-only.

Kovler says Lolla shows where the culture is, well ahead of Washington. Fair. But the drinks were hard to find on-site, available at only select bars — which looks less like scarcity marketing and more like a company reading the same calendar everyone else is.

📺 Trade To Black

Texas Erases $500 Million Hemp Market | TTB Weekly Recap

• Hemp regulation has fractured into four competing models. Texas now treats delta-8, delta-10 and THCP as controlled substances statewide, while Ohio, Florida and Delaware have taken sharply different approaches. All of it funnels toward the federal 0.4mg total-THC rule in November — which will effectively decide whose playbook becomes the national one.

• Veterans are becoming a real bipartisan force. Shadd breaks down how rescheduling has opened VA-funded psychedelic research, and how a Supreme Court ruling protecting gun rights for cannabis users has widened the coalition pushing reform.

• Record consumption, shrinking legal revenue. SAMHSA's newest survey puts 21.4 million Americans using cannabis 20+ days a month — more than daily alcohol or cigarette users — even as legal cannabis revenue fell for the first time ever.

• Earnings and M&A. Jushi (CSE: JUSH) (OTCQX: JUSHF) posted record wholesale revenue, Tilray (NASDAQ: TLRY) delivered record fiscal-year revenue alongside a wider net loss, and SNDL (NASDAQ: SNDL) leaned on a debt-free balance sheet heading into the Parallel restructuring. Vireo Growth (CSE: VREO) (OTCQX: VREOF) closed its 12th acquisition in eight months.